U.S., Nov. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07241104) titled 'A Study of AZD4063 in PLN R14del Dilated Cardiomyopathy' on Nov. 17.
Brief Summary: The purpose of the study is to assess the safety, tolerability and the pharmacokinetics (PK) of AZD4063 after single and multiple dose administration in participants with phospholamban (PLN) R14del dilated cardiomyopathy.
Study Start Date: Nov. 13
Study Type: INTERVENTIONAL
Condition:
Dilated Cardiomyopathy
Intervention:
DRUG: AZD4063
AZD4063 will be administered in the SAD and MAD part of the study as solution for injection via subcutaneous route of administration.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Published by HT...